Donor leukocyte infusions in acute myelogenous leukemia (Q73431984)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764364 AND SRC:MED&resulttype=core&format=json

3 November 2019

title

Donor leukocyte infusions in acute myelogenous leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764364 AND SRC:MED&resulttype=core&format=json

3 November 2019

author name string

D L Porter

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764364 AND SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764364 AND SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764364 AND SRC:MED&resulttype=core&format=json

3 November 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764364 AND SRC:MED&resulttype=core&format=json

3 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764364 AND SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1035-1037

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12764364 AND SRC:MED&resulttype=core&format=json

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Cytotoxic T‐lymphocyte (CTL) responses against acute or chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402950

7 January 2021